Irene Ghobrial, MD, discusses the importance of the data made available through the Multiple Myeloma Research Foundation’s CureCloud research study.
Irene Ghobrial, MD, director of the Clinical Investigator Research Program at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses the importance of the data made available through the Multiple Myeloma Research Foundation’s CureCloud research study.
The current standard in multiple myeloma practice is to measure disease burden and assess risk in bone marrow using tests such as fluorescence in situ hybridization (FISH) and cytogenetics. An advancement with CureCloud is the use of a unique, state-of-the-art CLIA-grade liquid biopsy, through which circulating cell-free DNA from a patient blood draw will be analyzed using next-generation sequencing (NGS) to obtain in-depth genomic information on each patient’s specific subtype of myeloma and detect and actionable genomic alterations.
Utilization of NGS is several steps up for precision medicine in myeloma, Ghobrial says. In addition, by participating in CureCloud, both physician and their patients will receive the genomic testing results of the patient’s myeloma, which can help inform and improve physician/patient conversations and decision-making around future treatment options, including clinical trials.
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More